Categories Earnings, LATEST, Other Industries

GW Pharmaceuticals beats revenue estimates in Q2

GW Pharmaceuticals (NASDAQ: GWPH)topped revenue estimates for the second quarter of 2019, sending the stock climbing over 11% during aftermarket hours on Tuesday. The consensus estimate was for earnings of $1.34 per share on revenue of $47 million.

Total revenue was $72 million compared to $3.3 million in the same period last year.

The company reported a net income of $79.7 million, or $0.21 per share, compared to a net loss of $84 million, or $0.25 per share, in the prior-year quarter.

During the quarter, sales of Epidiolex totaled $68.4 million. Over 12,000 patients have received Epidiolex prescriptions since launch and over 2,500 physicians have generated dispensed prescriptions since launch.

With regards to the European launch of Epidiolex, GW Pharma anticipates approval in early October on positive CHMP opinion. The company expects to launch in France, Germany and the UK by the fourth quarter with launches in Spain and Italy to follow in 2020.

The company is working on the development of Sativex for the treatment of multiple sclerosis spasticity. GW Pharma has already completed over 10 placebo-controlled trials in other conditions.

The company also believes there is potential for CBDV in the fields of autism and epilepsy. The open label study in Rett syndrome and seizures are ongoing.   

At June 30, 2019, GW Pharma had cash and cash equivalents of $583.7 million compared to $591.5 million as of December 31, 2018.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Aurora Cannabis (ACB) Earnings: 3Q21 Key Numbers

Aurora Cannabis Inc. (NYSE: ACB) reported third quarter 2021 earnings results today. Total revenues fell 25% year-over-year to CAD55.1 million. Adjusted EBITDA loss amounted to CAD24 million. Cash balance as

Walt Disney (DIS) Q2 revenue down 13%; earnings beat estimates

Media behemoth The Walt Disney Company (NYSE: DIS) reported second-quarter revenues that declined from last year as customers stayed away from theatres and parks due to pandemic-related safety issues and

Three key factors that bode well for Tattooed Chef (TTCF) going forward

Shares of Tattooed Chef Inc. (NASDAQ: TTCF) have gained 57% over the past 12 months but has dropped 25% since the start of this year. The sentiment on the stock


Add Comment
Viewing Highlight